Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma

LeeG.J.; MinJ.W.; SeoM.W.; LeeM.Y.; JinJ.Y.

首页> 外文期刊>The journal of obstetrics and gynaecology research >Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma

【24h】

Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma

机译：复发性原发性腹膜浆液性癌患者仅用一个周期的基于贝洛坎的化疗后的持久反应

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The efficacy of second-line chemotherapy for relapsed primary peritoneal serous carcinoma has been numerously reported, but reports on durable response after second-line therapy have been rare. We report the case of a 66-year-old woman with relapsed primary peritoneal serous carcinoma who showed durable response after just one cycle of second-line belotecan-based therapy. The response might be a complete pathologic remission. Considering the fact that our patient suffered from neutropenic sepsis during her treatment, we concluded that belotecan-based chemotherapy could be a good option for second-line chemotherapy in some selected patients, so patient selection should be carefully performed due to the toxicity of belotecan.

机译：二线化疗对复发性原发性腹膜浆液性癌的疗效已被大量报道，但二线治疗后持久反应的报道却很少。我们报道了一名66岁女性复发性原发性腹膜浆液性癌病例，该病例仅在二线基于贝洛坎的二线治疗后显示出持久的反应。反应可能是完全的病理缓解。考虑到我们的患者在治疗过程中患有中性粒细胞减少性败血症，因此我们得出结论，对于某些选定的患者，基于贝洛坎的化疗可能是二线化疗的较好选择，因此，由于贝洛坎的毒性，应谨慎选择患者。

著录项

来源
《The journal of obstetrics and gynaecology research》 |2014年第1期|共4页
作者
LeeG.J.; MinJ.W.; SeoM.W.; LeeM.Y.; JinJ.Y.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类妇产科学;
关键词
Belotecan; Ovarian neoplasms; Treatment efficacy;

机译：贝洛替康;卵巢肿瘤;治疗效果;

相似文献

外文文献
中文文献
专利

1. Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma [J] . LeeG.J., MinJ.W., SeoM.W., The journal of obstetrics and gynaecology research . 2014,第1期

机译：复发性原发性腹膜浆液性癌患者仅用一个周期的基于贝洛坎的化疗后的持久反应
2. A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy. [J] . Comander AH, Cannistra SA International journal of gynecological cancer: official journal of the International Gynecological Cancer Society . 2008,第1期

机译：低剂量，延长口服拓扑替康治疗晚期卵巢癌，输卵管癌或原发性腹膜浆液性癌的患者的可行性研究，这些患者在铂类化疗后已获得完全的临床反应。
3. Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation [J] . Gun Oh Chong, Ji Young Park, Hyun Jung Lee Case Reports & Clinical Practice Review . 2020,第2a3期

机译：在无BRCA突变的患者中，偶发性浆液性输卵管上皮内癌发展为原发性腹膜浆液性癌。
4. Is Primary Chemotherapy Useful for AiS Patients with Primary Invasive Breast Cancer [C] . S.M. Scholl, P. Beuzeboc, A.L. Harris, International Conference on "Adjuvant Therapy of Primary Breast Cancer" . 1998

机译：是主要的化疗，可用于AIS患有原发性侵袭性乳腺癌的患者
5. Dolo?anje Mutacij v Genih BRCA1/2 Iz citolo?kega Materiala Pri Raku jaj?nikov, Jajcevodov in Primarnem Peritonealnem Seroznem Karcinomu =BRCA1/2 mutation testing from cytological samples in patients with ovarian, tubal and primary peritoneal serous cancer [D] . Gornjec, Andreja. 2020

机译：从自我癌症中确定基因Krca1 / 2中的突变吗？
6. Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation [O] . Gun Oh Chong, Ji Young Park, Hyun Jung Lee 2020

机译：无BRCA突变的患者中偶然发生的浆液性输卵管上皮内癌发展为原发性腹膜浆液性癌。
7. Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation [O] . Gun Oh Chong, Ji Young Park, Hyun Jung Lee 2020

机译：偶然的静脉输卵管上皮癌，其在没有BRCA突变的患者中开发成初级腹膜浆液癌

Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma

摘要

著录项

相似文献

相关主题

期刊订阅